Why Is GLAUKOS CORP (GKOS) Stock Up Today?

Glaukos Corp (GKOS) shares rose 6.55% to close at $172.18. The primary driver for the move was the announcement of positive three-year results for its Epioxa treatment, which demonstrated durable clinical outcomes in keratoconus patients after a single dose.

What Happened

The company disclosed that its late-stage eye disease treatment shows lasting benefits, a finding that confirmed the durability of the clinical data. This announcement followed a period of strong momentum, with the stock printing 12 fresh 52-week highs on October 7, 2026. The positive data release served as the catalyst for the session's gains, pushing the share price higher despite the company's current unprofitable status.

What The Data Shows

Fundamentals indicate a market capitalization of $9.7 billion, with trailing twelve-month revenue growing 41.5%. However, the company remains unprofitable, reporting a trailing twelve-month EPS of negative $3.25 and a net margin of negative 30.7%. The stock trades within a 52-week range of $73.16 to $191.62, with a beta of 0.69. Options flow data indicated bearish hedging activity during the rally. Recent insider activity shows a pattern of selling, with 10 sales totaling $21.3 million in the last 90 days. Chief Development Officer Tomas Navratil recorded sales on October 5, September 25, and September 16, 2026. Congressional disclosures noted a sale of $50,001 to $100,000 by Donald J. Trump on July 29, 2026, and a purchase of $1,001 to $15,000 on June 15, 2026.

What To Watch

Glaukos is scheduled to release its third quarter 2026 financial results after market close on October 28. Investors will monitor how the company performs against expectations following the recent clinical data update.